A Woman’s Disease by the Numbers
Osteoporosis affects approximately 10 million Americans, 80% of whom are women. An additional 44 million have low bone density, placing them at elevated fracture risk. Hip fracture in women over 65 carries a one-year mortality rate that rivals many cancers — yet the condition that leads to it is preventable, detectable, and treatable with existing interventions that remain underutilized.
The central driver of bone loss in women is estrogen decline. The years immediately following menopause see the fastest rate of bone density loss in a woman’s lifetime — up to 20% of total bone mass in the first five to seven years after the final menstrual period. This window is both the greatest risk period and the greatest opportunity for intervention.
Osteoarthritis: Underrecognized, Undertreated
Osteoarthritis is the most common joint disease in the world, and women develop it at higher rates and with greater severity than men — particularly in the knee and hand. The sex differences in osteoarthritis are biologically meaningful: estrogen appears to have a protective effect on cartilage, and its loss at menopause is associated with accelerated joint degeneration.
Despite this, women’s pain from osteoarthritis is consistently undertreated. Studies show women are less likely than men to be referred for joint replacement surgery even when their functional impairment is equivalent or greater. The same gender pain gap that affects migraine and chronic pain management shapes orthopedic care.
The Research Gap
Musculoskeletal research has historically overrepresented male subjects, including in animal models and clinical trials. Fracture risk assessment tools were largely developed in white postmenopausal populations and perform less accurately in Black, Hispanic, and Asian women — contributing to disparities in screening and preventive intervention.
What We Track
We monitor bone density screening access and insurance coverage, NIH funding for sex-specific musculoskeletal research, updates to hormone therapy clinical guidance with implications for bone health, and policy affecting fracture prevention programs.
